• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Director Wampler Kira Scherer converted options into 2,000 shares and sold $141,780 worth of shares (2,000 units at $70.89) (SEC Form 4)

    3/5/25 4:05:34 PM ET
    $DOCS
    EDP Services
    Technology
    Get the next $DOCS alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    X
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Wampler Kira Scherer

    (Last) (First) (Middle)
    C/O DOXIMITY, INC.
    500 THIRD STREET

    (Street)
    SAN FRANCISCO CA 94107

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Doximity, Inc. [ DOCS ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    03/03/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Class A Common Stock 03/03/2025 C(1) 2,000 A (1) 18,618 D
    Class A Common Stock 03/03/2025 S(2) 2,000 D $70.89 16,618 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (Right to Buy) $1.54 03/03/2025 M 2,000 (3) 06/09/2030 Class B Common Stock(4) 2,000 $0 485,700 D
    Class B Common Stock (4) 03/03/2025 M 2,000 (4) (4) Class A Common Stock 2,000 $0 2,000 D
    Class B Common Stock (4) 03/03/2025 C(1) 2,000 (4) (4) Class A Common Stock 2,000 $0 0 D
    Explanation of Responses:
    1. Each share of Class B Common Stock, par value $0.001 per share (the "Class B Common Stock"), converted into one share of Class A Common Stock, par value $0.001 per share (the "Class A Common Stock"), at the option of the holder.
    2. The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2024.
    3. The stock option vested in 36 equal monthly installments after March 27, 2020, subject to the Reporting Person's continuous service relationship with the Issuer through each applicable vesting date. The stock option was granted on June 10, 2020.
    4. Each share of Class B Common Stock is convertible into one share of Class A Common Stock at any time at the option of the holder. Each share of Class B Common Stock held by the Reporting Person will automatically convert into one share of Class A Common Stock, upon the following: (1) the sale or transfer of such share of Class B Common Stock, except for certain permitted transfers described in the Issuer's amended and restated certificate of incorporation; (2) the death or incapacity of the Reporting Person; and (3) on the final conversion date, defined as the earlier of (a) the tenth anniversary of the effectiveness of the registration statement in connection with the Issuer's initial public offering; or (b) the date specified by a vote of the holders of at least 66 2/3% of the outstanding shares of Class B Common Stock, voting as a single class.
    Remarks:
    /s/ Jennifer Chaloemtiarana, Attorney-in-Fact 03/05/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $DOCS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DOCS

    DatePrice TargetRatingAnalyst
    6/2/2025$80.00Neutral → Buy
    BTIG Research
    2/7/2025$31.00 → $78.00Neutral → Overweight
    Piper Sandler
    2/7/2025$60.00 → $90.00Market Perform → Outperform
    Leerink Partners
    12/20/2024$55.00Equal-Weight
    Stephens
    12/4/2024$55.00Neutral
    Mizuho
    11/15/2024$58.00Neutral
    Goldman
    11/14/2024$33.00 → $53.00Underweight → Equal-Weight
    Morgan Stanley
    11/13/2024$40.00 → $60.00Buy → Hold
    Canaccord Genuity
    More analyst ratings

    $DOCS
    Leadership Updates

    Live Leadership Updates

    See more
    • Mendaera Closes $73M Series B Financing to Scale Robotics and AI Across Mainstream Medical Procedures

      With its first-of-its-kind platform, Mendaera is pioneering a new category in medical robotics Mendaera, Inc., a Silicon Valley-based healthcare technology company developing a handheld robotic interventional platform, announced today the close of $73 million in Series B funding led by Threshold Ventures, with participation from investors including Lux Capital, PFM Health Sciences, and Fred Moll (founder of Intuitive Surgical and Auris Health). The financing will further Mendaera's efforts to scale robotics and AI across mainstream medical procedures. The healthcare system is facing an increasing supply and demand crisis, where the ability to consistently deliver high-quality care to pati

      9/26/24 6:05:00 AM ET
      $DOCS
      $RELY
      $LVGO
      EDP Services
      Technology
      Business Services
      Consumer Discretionary
    • Doximity Appoints Phoebe Yang to Its Board of Directors

      Experienced director and executive brings health system and cloud expertise SAN FRANCISCO, Aug. 4, 2022 /PRNewswire/ -- Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced the appointment of Phoebe L. Yang to its Board of Directors. Ms. Yang has been General Manager at Amazon Web Services, Healthcare, and a member of the board of directors for CommonSpirit Health, one of the largest U.S. health systems. Ms. Yang is a long-time member of the Council on Foreign Relations, and has served as an appointee in two Presidential Administrations. In 2021, she was named one of Modern Healthcare's Top 100 Most Influential People in Healthcare and one

      8/4/22 4:02:00 PM ET
      $DOCS
      EDP Services
      Technology